Status:

ACTIVE_NOT_RECRUITING

Voice-Activated Technology to Improve Mobility in Multimorbid, Frail, Homebound Older Adults (EngAGE)

Lead Sponsor:

University of Chicago

Collaborating Sponsors:

Rush University

National Opinion Research Center

Conditions:

Frailty

Eligibility:

All Genders

60+ years

Phase:

NA

Brief Summary

The purpose of this study is to test the efficacy of EngAGE (an interactive, voice-activated app) vs usual care on improving older adult physical and social function.

Detailed Description

Physical activity is essential for all age groups, across all comorbidities and geriatric syndromes; it has been described as the 'ideal' intervention for aging. Increasing physical activity among hom...

Eligibility Criteria

Inclusion

  • age greater than or equal to 60 years
  • has at least 2 chronic conditions
  • requires any assistance to leave the home (this may include requiring someone to drive, requiring the use of a cane or walker, or similar)
  • can read 14 point font from a 2-foot distance on a tablet-sized screen
  • can hear spoken voice from 2-foot distance
  • SPPB score of less than or equal to 9 but greater than 3 on a 12-point scale to target moderate but not severe functional impairment.

Exclusion

  • reported history of moderate to advanced cognitive impairment;
  • inability to stand unassisted;
  • inability to understand English (because the intervention is currently only available in English);
  • life expectancy less than 12 months or enrolled in Hospice;
  • a medical condition making unsupervised physical activity potentially unsafe including: stroke within prior 12 months, acute myocardial infarction or unstable angina in the prior 6 months, uncontrolled arrhythmias, dissecting aortic aneurysm, acute endo/pericarditis, acute thromboembolism, acute or severe heart or respiratory failure, uncontrolled hypertension greater than 180/100, fracture or joint replacement within the prior 3 months, infections affecting one's general health condition, severe peripheral vascular disease.
  • severe functional impairment as indicated by an SPPB score less than 3 (out of 12);
  • baseline Montreal Cognitive Assessment of less than or equal to 18/30;
  • inability to understand consent (teach back).

Key Trial Info

Start Date :

October 26 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2026

Estimated Enrollment :

137 Patients enrolled

Trial Details

Trial ID

NCT05337514

Start Date

October 26 2022

End Date

June 30 2026

Last Update

October 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Chicago

Chicago, Illinois, United States, 60637